14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
ARIA vs INCY
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ARIA vs INCY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
INCY Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)
INCY Overall Winner
6-Pillar Tally: ARIA 0 – 6 INCY
Matrix Metrics: ARIA 0 – 10 INCY
As of Nov 16, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over ARIA (ARIA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARIA carries a Unified Composite Score of 47.7/100 (HOLD) at $21.03 (N/M Forward P/E, N/A operating margin), whereas INCY carries 58.9/100 (HOLD) at $120.27 (13.9x Forward P/E, 32.2% operating margin).
ARIA
US Equity
ARIA
Institutional Equity
Market Cap
N/A
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.92β · 43% Vol
Unified Composite Score
47.7 / 100
HOLD
Tech 50.0
Fund 52.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
INCY
NASDAQ
Head-to-Head Winner
Incyte Genomics Inc
Services-Commercial Physical & Biological Research
Market Cap
$24.7B
TTM Revenue
$6.01B
Forward P/E
13.9x
Beta / 30D Vol
0.30β · 35% Vol
Unified Composite Score
58.9 / 100
HOLD
Tech 45.0
Fund 56.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 52.8 · SMA20: $118.61 · SMA50: $119.05
6-Pillar Scorecard Institutional Category Breakdown (ARIA 0 – 6 INCY)
Columns: Metric · ARIA · INCY
1. Valuation Multiples
INCY
Forward P/E
N/M
13.9x
Trailing P/E
N/M
61.7x
PEG Ratio
N/M
10.82x
EV / Revenue
N/M
3.6x
2. Growth & Scale
INCY
Revenue Growth (YoY)
N/A
+14.0%
Earnings Growth (YoY)
N/A
+37.7%
TTM Revenue (USD)
N/A
$6.01B
Market Cap
N/A
$24.7B
3. Profitability & Quality
INCY
Gross Margin
N/A
56.0%
Operating Margin
N/A
32.2%
Net Profit Margin
N/A
6.7%
Return on Equity (ROE)
N/A
7.8%
4. Balance Sheet & Cash Flow
INCY
Cash Generation (TTM)
N/A
$680M
Cash Flow Margin
N/A
11.3%
Net Cash / Leverage
N/A ROE
$3.24B Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
INCY
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
41.7% (73rd %ile)
Put/Call OI Skew
N/A
1.62x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
INCY
OpEx & R&D Intensity
N/A
23.8% of Rev ($1.43B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Institutional Equity Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ARIA (0) vs INCY (10)
Institutional Metric
ARIA
INCY
Criterion
Row Edge
Market Capitalization
Scale
N/A
$24.7B
Larger Scale
INCY
Trailing P/E Ratio
Valuation
N/M
61.7x
Lower Multiple
INCY
Forward P/E Ratio
Valuation
N/M
13.9x
Lower Multiple
INCY
Revenue Growth (YoY)
Growth
N/A
+14.0%
Higher Growth
INCY
Operating Margin (TTM)
Profitability
N/A
32.2%
Higher Margin
INCY
Net Profit Margin
Profitability
N/A
6.7%
Higher Margin
INCY
Return on Equity (ROE)
Capital Efficiency
N/A
7.8%
Higher ROE
INCY
52-Week Range Position
Momentum
0% ($21–$27)
72% ($89–$133)
Stronger Trend
INCY
Beta / 30D Volatility
Risk Regime
1.92β · 43% Vol
0.30β · 35% Vol
Lower Realized Risk
INCY
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD)
58.9 / 100 (HOLD)
Higher Composite
INCY
Trailing 12M Revenue (USD)
Operating Scale
N/A
$6.01B
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A
56.0%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev
10.82x PEG · 3.6x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE)
$680M ($3.24B Net Cash)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
INCY +17.92 pp
ARIA:
-11.55%
·
INCY:
+6.37%
3M Horizon
INCY +13.62 pp
ARIA:
-16.21%
·
INCY:
-2.59%
6M Horizon
INCY +15.92 pp
ARIA:
-16.97%
·
INCY:
-1.05%
1Y Horizon
INCY +15.92 pp
ARIA:
-16.97%
·
INCY:
-1.05%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARIA vs INCY. Trailing 12-month operating profitability (ARIA N/A vs INCY 32.2%) and valuation multiples (ARIA N/M vs INCY 13.9x Forward P/E) are benchmarked directly in Pillar 4 below.
ARIA ADR TTM Benchmark
FX-Normalized USD
TTM Revenue N/A
Gross Margin N/A
Op. Margin N/A
ROE / Fwd P/E N/A · N/M
INCY ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $6.01B
Gross Margin 56.0%
Op. Margin 32.2%
ROE / Fwd P/E 7.8% · 13.9x
ARIA
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
INCY
CONSOLIDATION
78d in phase · OBV DISTRIBUTION
Current IV
41.7%
IV Percentile
73rd %ile
Put/Call OI Skew
1.62x (Put-Skewed)
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
ARIA Moat Profile
Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
INCY Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $24.7B market capitalization and 32.2% operating margin.
OpEx & R&D Reinvestment
23.8% of Rev ($1.43B)
90D Engineering Disclosures
0 Published
Investor FAQ ARIA vs INCY Key Questions & Quantitative Answers
Is ARIA or INCY a better stock to buy right now?
As of Nov 16, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over ARIA (ARIA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARIA carries a Unified Composite Score of 47.7/100 (HOLD) at $21.03 (N/M Forward P/E, N/A operating margin), whereas INCY carries 58.9/100 (HOLD) at $120.27 (13.9x Forward P/E, 32.2% operating margin). Technically, ARIA sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and INCY sits in a Neutral phase (RSI 52.8, CONSOLIDATION options structure).
Does ARIA or INCY have stronger revenue and earnings growth?
INCY leads the Growth & Scale pillar: ARIA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with INCY at +14.0% YoY revenue growth and +37.7% YoY earnings growth on $6.01B TTM revenue (56.0% gross margin, 32.2% operating margin). On trailing 12-month operating scale, ARIA generates N/A in USD-normalized revenue versus $6.01B for INCY. In operating R&D and SG&A reinvestment, ARIA deploys N/A (0 90-day corporate R&D disclosures) versus 23.8% of Rev ($1.43B) (0 disclosures) for INCY.
Is ARIA or INCY cheaper on valuation?
INCY screens cheaper on headline valuation multiples. ARIA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas INCY trades at 13.9x Forward P/E, 61.7x Trailing P/E, 10.82x PEG, and 3.6x EV/Revenue (11.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARIA (N/A ROE) versus INCY (7.8% ROE) capital efficiency.
How is options market volatility positioned on ARIA vs INCY?
In options market volatility and institutional positioning, ARIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 43% Vol realized risk). By comparison, INCY carries 41.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 35% Vol realized risk).
ARIA (ARIA) Research Suite
Incyte Genomics Inc (INCY) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.